Showing results (61-70 of 71) with videos related to
Sort By:
Pageof 8
Clinica Chimica Acta; International Journal of Clinical Chemistry|June 21, 2006
Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese malesWei Zhang, Bang-Ning Yu, Yi-Jing He, et al.European Journal of Clinical Pharmacology|January 28, 2009
Effects of allicin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypesLi-Jun Yang, Lan Fan, Zhao-Qian Liu, et al.Plos One|November 27, 2014
Searching the cytochrome p450 enzymes for the metabolism of meranzin hydrate: a prospective antidepressant originating from Chaihu-Shugan-SanXi Huang, Ying Guo, Wei-Hua Huang, et al.Pakistan Journal of Pharmaceutical Sciences|April 30, 2013
Effect of pitavastatin in different SLCO1B1 backgrounds on repaglinide pharmacokinetics and pharmacodynamics in healthy Chinese malesJie Zhu, Min Song, Hong-Yi Tan, et al.British Journal of Clinical Pharmacology|June 27, 2006
Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinideWei Zhang, Yi-Jing He, Chun-Ting Han, et al.Acta Pharmacologica Sinica|July 24, 2012
Pharmacokinetic interactions between ilaprazole and clarithromycin following ilaprazole, clarithromycin and amoxicillin triple therapyShan Cao, Gan Zhou, Dong-sheng Ou-Yang, et al.Clinica Chimica Acta; International Journal of Clinical Chemistry|April 21, 2009
Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphismYi-Jing He, Wei Zhang, Yao Chen, et al.Xenobiotica; the Fate of Foreign Compounds in Biological Systems|October 14, 2017
The potent mechanism-based inactivation of CYP2D6 and CYP3A4 with fusidic acid in in vivo bioaccumulationXiu-Xian Lin, Guang-Hui Lian, Ying Xu, et al.Journal of Analytical Methods in Chemistry|January 27, 2022
A Joint Technology Combining the Advantages of Capillary Microsampling with Mass Spectrometry Applied to the Trans-Resveratrol Pharmacokinetic Study in MiceYing Xu, Song-Xia Zhang, Jing Guo, et al.Plos One|August 14, 2013
Polymorphism of ORM1 is associated with the pharmacokinetics of telmisartanWang-Qing Chen, Yan Shu, Qing Li, et al.Pageof 8